
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : uBriGene Biosciences International
Deal Size : Undisclosed
Deal Type : Collaboration
UbriGene Biosciences, Circurna Partner to Accelerate Circular RNA/LNP Therapeutics
Details : The collaboration aims to advance the development of an undisclosed oligonucleotide product in cancer.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : uBriGene Biosciences International
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : GATC Health
Deal Size : Undisclosed
Deal Type : Collaboration
Circurna Engages GATC Health for AI-Powered Discovery to Accelerate ciRNA Therapeutics
Details : The collaboration is designed to enhance the design, delivery, and targeting of Circurna’s next-generation RNA therapeutics.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
August 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : GATC Health
Deal Size : Undisclosed
Deal Type : Collaboration
